The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
1996

EGF Receptor mRNA in Ovarian Cancer

Sample size: 97 publication Evidence: moderate

Author Information

Author(s): JMS Bartlett, SP Langdon, BJB Simpson, M Stewart, D Katsaros, P Sismondi, S Love, WN Scott, ARW Williams, AM Lessells, KG Macleod, JF Smyth, WR Miller

Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh

Hypothesis

The expression of EGF receptor mRNA is associated with poor prognosis in primary ovarian cancer.

Conclusion

The presence of EGF receptor mRNA is linked to reduced survival in patients with malignant ovarian tumors.

Supporting Evidence

  • 70% of malignant tumors expressed EGF receptor mRNA.
  • Patients with EGF receptor mRNA positive tumors had significantly reduced survival.
  • EGF receptor mRNA expression was significantly associated with serous histology.

Takeaway

This study found that a specific marker in ovarian cancer cells, called EGF receptor mRNA, can help predict how well patients might do after treatment.

Methodology

The study used reverse transcriptase-polymerase chain reaction (RT-PCR) to analyze mRNA expression in ovarian tumor samples.

Limitations

The study's findings may not apply to all types of ovarian tumors, as it primarily focused on malignant cases.

Participant Demographics

The study included 97 patients with histologically confirmed primary ovarian tumors, comprising 76 malignant, 6 borderline, and 15 benign tumors.

Statistical Information

P-Value

0.0015 for EGF receptor and TGF-a association; 0.030 for EGF receptor and survival

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication